logo-loader
viewVolitionRx

VolitionRx CEO discusses 'spectacular' results from Nu.Q proof of concept study

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds discusses with Proactive London's Andrew Scott the results from the latest proof of concept study on its Nu.Q cancer-test assay.

He says the finding's have revealed an impressive ability to detect with accuracy non-Hodgkins lymphoma (NHL) and other types of leukemia.

Quick facts: VolitionRx

Price: 3.29 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $152.08 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet. Heading into 2020, Reynolds says the company's well...

on 21/2/20

2 min read